EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling

Laila Tanana iD, Asam Latif, Prasad S Nishtala, Timothy F Chen

Journal of Attention Disorders · 2024

DOI: 10.1177/10870547231224088 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Attention Disorders, 2024. Verfasst von Laila Tanana und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Drug Labeling, Central Nervous System Stimulants, Drug Approval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to compare the approval of medicines for attention deficit/hyperactivity disorder (ADHD) for pediatric patients across five countries.

Method

A document analysis was completed, using the drug labeling for ADHD medicines from five countries; United Kingdom, Australia, New Zealand, Canada and United States (US). Comparisons of available formulations and approval information for ADHD medicine use in pediatric patients were made.

Results

The US had the highest number of approved medicines and medicine forms across the studied countries (29 medicine forms for 10 approved medicines). Approved age and dosage variations across countries and missing dosage information were identified in several drug labeling.

Conclusions

The discrepancies in approval information in ADHD medicine drug labeling and differing availability of medicine formulations across countries suggest variations in the management of ADHD across countries. The update of drug labeling and further research into reasons for variability and impact on practice are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityDrug LabelingCentral Nervous System StimulantsDrug ApprovalHumansNew ZealandUnited StatesAustraliaCanadaChildUnited KingdomDocument Analysis

Stichwörter der Autor:innen

ADHDchildrenmedicationmethylphenidatepsychostimulant

Substanzen

Central Nervous System Stimulants

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • University of Nottingham, Nottingham, UK.
  • Department of Life Sciences, University of Bath, Bath, UK.

ORCID-Profile: Laila Tanana

Zitieren

APA

Tanana, L., Latif, A., Nishtala, P. S., & Chen, T. F. (2024). Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling. Journal of Attention Disorders. https://doi.org/10.1177/10870547231224088

Vancouver

Tanana L, Latif A, Nishtala PS, Chen TF. Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling. Journal of Attention Disorders. 2024. doi:10.1177/10870547231224088

BibTeX
@article{Tanana2024,
  author = {Tanana, Laila and Latif, Asam and Nishtala, Prasad S and Chen, Timothy F},
  title = {Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling},
  journal = {Journal of Attention Disorders},
  year = {2024},
  doi = {10.1177/10870547231224088}
}
Kostenlos starten →